PRQR Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

1.699

Open

1.650

VWAP

1.63

Vol

1.09M

Mkt Cap

234.26M

Low

1.590

Amount

1.79M

EV/EBITDA(TTM)

Total Shares

141.12M

153.24M

EV/OCF(TTM)

P/S(TTM)

11.50

ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).

Events Timeline

(ET)

2026-07-06

16:30:00

Company Does Not Sell 3.03M Ordinary Shares

2026-06-25 (ET)

2026-06-25

07:00:00

ProQR Therapeutics Prices 27.6M Share Offering at $1.81

2026-06-25

07:00:00

ProQR Therapeutics Reports Positive Phase 1 Data for AX-0810

News

8.5

06-26NASDAQ.COM

ProQR Announces Underwritten Direct Offering, Shares Drop 20%

8.5

06-25seekingalpha

ProQR Therapeutics Prices $50M Direct Offering of 27.6M Shares

9.0

06-25seekingalpha

ProQR Therapeutics Reports Positive Phase 1 Data for AX-0810

9.0

06-25NASDAQ.COM

ProQR Reports Positive Data from AX-0810 Phase 1 Study

9.0

06-25Newsfilter

Positive Phase 1 Study Results for AX-0810 Indicate Significant NTCP Modulation

8.5

06-25Newsfilter

ProQR Therapeutics Completes $50 Million Financing

3 Analyst Rating

Wall Street analysts forecast PRQR stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

5.00

Averages

8.67

High

12.00

Current: 0.000

Low

5.00

Averages

8.67

High

12.00

Raymond James

Strong Buy

downgrade

$14 -> $10

AI Analysis

2026-06-26

Reason

Raymond James

Price Target

$14 -> $10

AI Analysis

2026-06-26

downgrade

Strong Buy

Reason

Raymond James lowered the firm's price target on ProQR Therapeutics to $10 from $14 and keeps a Strong Buy rating on the shares. Based on the thesis that early data from the Axiomer RNA editing platform in healthy volunteers may translate into an effective therapy for biliary atresia, the initial Phase 1 dataset and additional key takeaways from ProQR's presentation further support a positive outlook on Axiomer-based candidates in biliary atresia and beyond, the analyst tells investors in a research note.

JonesResearch

Catherine Novack

Buy

downgrade

$11 -> $10

2026-06-26

Reason

JonesResearch

Catherine Novack

Price Target

$11 -> $10

2026-06-26

downgrade

Buy

Reason

JonesResearch analyst Catherine Novack lowered the firm's price target on ProQR Therapeutics to $10 from $11 and keeps a Buy rating on the shares. The firm cites the company's increased share count for the target cut. It sees a buying opportunity on weakness from the topline RNA editing data for AX-0810 in healthy volunteers. The study "hot on all key biomarkers," the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PRQR

Unlock Now

Valuation Metrics

The current forward P/E ratio for ProQR Therapeutics NV (PRQR.O) is 0.00, compared to its 5-year average forward P/E of -5.15. For a more detailed relative valuation and DCF analysis to assess ProQR Therapeutics NV's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.15

Current PE

0.00

Overvalued PE

-2.41

Undervalued PE

-7.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.53

Current EV/EBITDA

-1.60

Overvalued EV/EBITDA

0.53

Undervalued EV/EBITDA

-3.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

40.78

Current PS

14.64

Overvalued PS

149.72

Undervalued PS

-68.16

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

need penny stocks Formed two bottoms

Intellectia · 130 candidates

Price: $0.50 - $5.00Moving Average Relationship: PriceAboveMA5, PriceAboveMA20, PriceCrossAboveMA20Candlestick Pattern: InverseHeadAndShoulder, AscendingTriangle, WhiteCandlestick, LowerShadowSupport Resistance Relationship: PriceBreakResistance, PriceAroundSupport

Ticker

Name

Market Cap$

LNKS

Linkers Industries Ltd

4.31M

CDT

CDT Equity Inc

4.96M

APWC

Asia Pacific Wire & Cable Corporation Ltd

82.05M

NEOV

NeoVolta Inc

157.37M

EXFY

Expensify Inc

150.44M

KALA

KALA BIO Inc

67.11M

Whales Holding PRQR

Kynam Capital Management, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is ProQR Therapeutics NV (PRQR) stock price today?

The current price of PRQR is 1.615 USD — it has decreased -2.71

What is ProQR Therapeutics NV (PRQR)'s business?

What is the price predicton of PRQR Stock?

Wall Street analysts forecast PRQR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRQR is8.67 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.